Avenge Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://avengebio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Phase 1
Terminated
- Conditions
- Serous Adenocarcinoma of OvarySerous Adenocarcinoma of Primary PeritoneumNeoplasm, OvarianPrimary Peritoneal Cavity CancerPrimary Peritoneal CarcinomaHigh Grade Serous AdenocarcinomaFallopian Tube CancerAdenocarcinoma Ovary
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Avenge Bio, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05538624
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
News
No news found